Is Uber Finally on the Path to Consistent Profitability?
After posting massive losses quarter after quarter for years, Uber…
Sell
47
AZN Quote, Financials, Valuation and Earnings
Last price:
$67.09
Seasonality move
:
4.94%
Day range:
$67.32 - $68.40
52-week range:
$61.24 - $87.68
Dividend yield:
2.28%
P/E ratio:
30.10x
P/S ratio:
3.92x
P/B ratio:
5.17x
Volume:
4.4M
Avg. volume:
6.4M
1-year change:
-1.25%
Market cap:
$210.4B
Revenue:
$54.1B
EPS (TTM):
$2.26
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
AZN
AstraZeneca PLC
|
$13.7B | $1.11 | 8.46% | 83.1% | $85.68 |
|
AMGN
Amgen
|
$8B | $4.26 | 5.51% | 285.64% | $317.12 |
|
GSK
GSK PLC
|
$9.6B | $0.98 | 2.49% | 46.01% | $43.55 |
|
JNJ
Johnson & Johnson
|
$21.6B | $2.58 | 1.6% | 37.92% | $169.73 |
|
MRNA
Moderna
|
$126.2M | -$3.10 | -19.37% | -0.05% | $51.31 |
|
SNY
Sanofi SA
|
$11.1B | $0.95 | -15.85% | 82.5% | $63.84 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
AZN
AstraZeneca PLC
|
$67.87 | $85.68 | $210.4B | 30.10x | $1.05 | 2.28% | 3.92x |
|
AMGN
Amgen
|
$295.30 | $317.12 | $158.6B | 39.11x | $2.38 | 3.09% | 4.77x |
|
GSK
GSK PLC
|
$35.68 | $43.55 | $72.7B | 22.54x | $0.40 | 4.36% | 1.84x |
|
JNJ
Johnson & Johnson
|
$153.62 | $169.73 | $370.2B | 17.09x | $1.24 | 3.23% | 4.17x |
|
MRNA
Moderna
|
$26.24 | $51.31 | $10.1B | -- | $0.00 | 0% | 3.18x |
|
SNY
Sanofi SA
|
$50.60 | $63.84 | $126.9B | 20.25x | $2.04 | 7.78% | 2.64x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
AZN
AstraZeneca PLC
|
41.27% | -0.160 | -- | 0.74x |
|
AMGN
Amgen
|
91.09% | 0.284 | 43.85% | 0.84x |
|
GSK
GSK PLC
|
53.74% | -0.068 | 29.19% | 0.49x |
|
JNJ
Johnson & Johnson
|
33.88% | 0.428 | -- | 0.86x |
|
MRNA
Moderna
|
-- | 0.004 | -- | 3.45x |
|
SNY
Sanofi SA
|
17.11% | 0.103 | 13.73% | 0.64x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
AZN
AstraZeneca PLC
|
$12.2B | $2B | 9.88% | 17.77% | 14.07% | $2B |
|
AMGN
Amgen
|
$6B | $2.3B | 5.97% | 66.87% | 16.83% | $4.4B |
|
GSK
GSK PLC
|
$7.1B | $2.8B | 8.51% | 19.22% | 8.71% | $1.5B |
|
JNJ
Johnson & Johnson
|
$14.5B | $6.2B | 20.26% | 19.98% | 28.32% | $4.8B |
|
MRNA
Moderna
|
$217M | -$1.2B | -29.09% | -29.09% | -123.22% | $303M |
|
SNY
Sanofi SA
|
$5.7B | $917.8M | 6.07% | 7.55% | 4.64% | -$498.5M |
AstraZeneca PLC vs. Competitors
-
Which has Higher Returns AZN or AMGN?
Amgen has a net margin of 10.07% compared to AstraZeneca PLC's net margin of 6.9%. AstraZeneca PLC's return on equity of 17.77% beat Amgen's return on equity of 66.87%.
Company Gross Margin Earnings Per Share Invested Capital AZNAstraZeneca PLC81.7% $0.48 $69.5B AMGNAmgen65.75% $1.16 $66B -
What do Analysts Say About AZN or AMGN?
AstraZeneca PLC has a consensus price target of $85.68, signalling upside risk potential of 26.25%. On the other hand Amgen has an analysts' consensus of $317.12 which suggests that it could grow by 7.39%. Given that AstraZeneca PLC has higher upside potential than Amgen, analysts believe AstraZeneca PLC is more attractive than Amgen.
Company Buy Ratings Hold Ratings Sell Ratings AZNAstraZeneca PLC6 1 0 AMGNAmgen9 14 2 -
Is AZN or AMGN More Risky?
AstraZeneca PLC has a beta of 0.485, which suggesting that the stock is 51.487% less volatile than S&P 500. In comparison Amgen has a beta of 0.583, suggesting its less volatile than the S&P 500 by 41.682%.
-
Which is a Better Dividend Stock AZN or AMGN?
AstraZeneca PLC has a quarterly dividend of $1.05 per share corresponding to a yield of 2.28%. Amgen offers a yield of 3.09% to investors and pays a quarterly dividend of $2.38 per share. AstraZeneca PLC pays 65.8% of its earnings as a dividend. Amgen pays out 118.14% of its earnings as a dividend. AstraZeneca PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Amgen's is not.
-
Which has Better Financial Ratios AZN or AMGN?
AstraZeneca PLC quarterly revenues are $14.9B, which are larger than Amgen quarterly revenues of $9.1B. AstraZeneca PLC's net income of $1.5B is higher than Amgen's net income of $627M. Notably, AstraZeneca PLC's price-to-earnings ratio is 30.10x while Amgen's PE ratio is 39.11x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AstraZeneca PLC is 3.92x versus 4.77x for Amgen. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AZNAstraZeneca PLC3.92x 30.10x $14.9B $1.5B AMGNAmgen4.77x 39.11x $9.1B $627M
-
Which has Higher Returns AZN or GSK?
GSK PLC has a net margin of 10.07% compared to AstraZeneca PLC's net margin of 5.1%. AstraZeneca PLC's return on equity of 17.77% beat GSK PLC's return on equity of 19.22%.
Company Gross Margin Earnings Per Share Invested Capital AZNAstraZeneca PLC81.7% $0.48 $69.5B GSKGSK PLC68.47% $0.26 $36.4B -
What do Analysts Say About AZN or GSK?
AstraZeneca PLC has a consensus price target of $85.68, signalling upside risk potential of 26.25%. On the other hand GSK PLC has an analysts' consensus of $43.55 which suggests that it could grow by 22.05%. Given that AstraZeneca PLC has higher upside potential than GSK PLC, analysts believe AstraZeneca PLC is more attractive than GSK PLC.
Company Buy Ratings Hold Ratings Sell Ratings AZNAstraZeneca PLC6 1 0 GSKGSK PLC2 3 1 -
Is AZN or GSK More Risky?
AstraZeneca PLC has a beta of 0.485, which suggesting that the stock is 51.487% less volatile than S&P 500. In comparison GSK PLC has a beta of 0.579, suggesting its less volatile than the S&P 500 by 42.135%.
-
Which is a Better Dividend Stock AZN or GSK?
AstraZeneca PLC has a quarterly dividend of $1.05 per share corresponding to a yield of 2.28%. GSK PLC offers a yield of 4.36% to investors and pays a quarterly dividend of $0.40 per share. AstraZeneca PLC pays 65.8% of its earnings as a dividend. GSK PLC pays out 94.91% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios AZN or GSK?
AstraZeneca PLC quarterly revenues are $14.9B, which are larger than GSK PLC quarterly revenues of $10.4B. AstraZeneca PLC's net income of $1.5B is higher than GSK PLC's net income of $530.1M. Notably, AstraZeneca PLC's price-to-earnings ratio is 30.10x while GSK PLC's PE ratio is 22.54x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AstraZeneca PLC is 3.92x versus 1.84x for GSK PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AZNAstraZeneca PLC3.92x 30.10x $14.9B $1.5B GSKGSK PLC1.84x 22.54x $10.4B $530.1M
-
Which has Higher Returns AZN or JNJ?
Johnson & Johnson has a net margin of 10.07% compared to AstraZeneca PLC's net margin of 50.24%. AstraZeneca PLC's return on equity of 17.77% beat Johnson & Johnson's return on equity of 19.98%.
Company Gross Margin Earnings Per Share Invested Capital AZNAstraZeneca PLC81.7% $0.48 $69.5B JNJJohnson & Johnson66.4% $4.54 $108.1B -
What do Analysts Say About AZN or JNJ?
AstraZeneca PLC has a consensus price target of $85.68, signalling upside risk potential of 26.25%. On the other hand Johnson & Johnson has an analysts' consensus of $169.73 which suggests that it could grow by 10.49%. Given that AstraZeneca PLC has higher upside potential than Johnson & Johnson, analysts believe AstraZeneca PLC is more attractive than Johnson & Johnson.
Company Buy Ratings Hold Ratings Sell Ratings AZNAstraZeneca PLC6 1 0 JNJJohnson & Johnson7 11 0 -
Is AZN or JNJ More Risky?
AstraZeneca PLC has a beta of 0.485, which suggesting that the stock is 51.487% less volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.490, suggesting its less volatile than the S&P 500 by 50.995%.
-
Which is a Better Dividend Stock AZN or JNJ?
AstraZeneca PLC has a quarterly dividend of $1.05 per share corresponding to a yield of 2.28%. Johnson & Johnson offers a yield of 3.23% to investors and pays a quarterly dividend of $1.24 per share. AstraZeneca PLC pays 65.8% of its earnings as a dividend. Johnson & Johnson pays out 84.05% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios AZN or JNJ?
AstraZeneca PLC quarterly revenues are $14.9B, which are smaller than Johnson & Johnson quarterly revenues of $21.9B. AstraZeneca PLC's net income of $1.5B is lower than Johnson & Johnson's net income of $11B. Notably, AstraZeneca PLC's price-to-earnings ratio is 30.10x while Johnson & Johnson's PE ratio is 17.09x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AstraZeneca PLC is 3.92x versus 4.17x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AZNAstraZeneca PLC3.92x 30.10x $14.9B $1.5B JNJJohnson & Johnson4.17x 17.09x $21.9B $11B
-
Which has Higher Returns AZN or MRNA?
Moderna has a net margin of 10.07% compared to AstraZeneca PLC's net margin of -117.16%. AstraZeneca PLC's return on equity of 17.77% beat Moderna's return on equity of -29.09%.
Company Gross Margin Earnings Per Share Invested Capital AZNAstraZeneca PLC81.7% $0.48 $69.5B MRNAModerna22.7% -$2.91 $10.9B -
What do Analysts Say About AZN or MRNA?
AstraZeneca PLC has a consensus price target of $85.68, signalling upside risk potential of 26.25%. On the other hand Moderna has an analysts' consensus of $51.31 which suggests that it could grow by 95.54%. Given that Moderna has higher upside potential than AstraZeneca PLC, analysts believe Moderna is more attractive than AstraZeneca PLC.
Company Buy Ratings Hold Ratings Sell Ratings AZNAstraZeneca PLC6 1 0 MRNAModerna5 17 1 -
Is AZN or MRNA More Risky?
AstraZeneca PLC has a beta of 0.485, which suggesting that the stock is 51.487% less volatile than S&P 500. In comparison Moderna has a beta of 2.231, suggesting its more volatile than the S&P 500 by 123.128%.
-
Which is a Better Dividend Stock AZN or MRNA?
AstraZeneca PLC has a quarterly dividend of $1.05 per share corresponding to a yield of 2.28%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AstraZeneca PLC pays 65.8% of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend. AstraZeneca PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios AZN or MRNA?
AstraZeneca PLC quarterly revenues are $14.9B, which are larger than Moderna quarterly revenues of $956M. AstraZeneca PLC's net income of $1.5B is higher than Moderna's net income of -$1.1B. Notably, AstraZeneca PLC's price-to-earnings ratio is 30.10x while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AstraZeneca PLC is 3.92x versus 3.18x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AZNAstraZeneca PLC3.92x 30.10x $14.9B $1.5B MRNAModerna3.18x -- $956M -$1.1B
-
Which has Higher Returns AZN or SNY?
Sanofi SA has a net margin of 10.07% compared to AstraZeneca PLC's net margin of 6.54%. AstraZeneca PLC's return on equity of 17.77% beat Sanofi SA's return on equity of 7.55%.
Company Gross Margin Earnings Per Share Invested Capital AZNAstraZeneca PLC81.7% $0.48 $69.5B SNYSanofi SA70.24% $0.29 $97.7B -
What do Analysts Say About AZN or SNY?
AstraZeneca PLC has a consensus price target of $85.68, signalling upside risk potential of 26.25%. On the other hand Sanofi SA has an analysts' consensus of $63.84 which suggests that it could grow by 26.17%. Given that AstraZeneca PLC has higher upside potential than Sanofi SA, analysts believe AstraZeneca PLC is more attractive than Sanofi SA.
Company Buy Ratings Hold Ratings Sell Ratings AZNAstraZeneca PLC6 1 0 SNYSanofi SA5 2 0 -
Is AZN or SNY More Risky?
AstraZeneca PLC has a beta of 0.485, which suggesting that the stock is 51.487% less volatile than S&P 500. In comparison Sanofi SA has a beta of 0.578, suggesting its less volatile than the S&P 500 by 42.246%.
-
Which is a Better Dividend Stock AZN or SNY?
AstraZeneca PLC has a quarterly dividend of $1.05 per share corresponding to a yield of 2.28%. Sanofi SA offers a yield of 7.78% to investors and pays a quarterly dividend of $2.04 per share. AstraZeneca PLC pays 65.8% of its earnings as a dividend. Sanofi SA pays out 84.6% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios AZN or SNY?
AstraZeneca PLC quarterly revenues are $14.9B, which are larger than Sanofi SA quarterly revenues of $8.1B. AstraZeneca PLC's net income of $1.5B is higher than Sanofi SA's net income of $531.9M. Notably, AstraZeneca PLC's price-to-earnings ratio is 30.10x while Sanofi SA's PE ratio is 20.25x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AstraZeneca PLC is 3.92x versus 2.64x for Sanofi SA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AZNAstraZeneca PLC3.92x 30.10x $14.9B $1.5B SNYSanofi SA2.64x 20.25x $8.1B $531.9M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
How High Will MSTY Go By 2030?
YieldMax’s MSTR Option Income Strategy ETF (MSTY) is a high-yield…
Will NVIDIA Stock Bounce Back?
After the wild market moves during February and March, investors…
Stock Ideas
Buy
55
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 38x
Alerts
Sell
45
DSDVY alert for Apr 16
DSV AS [DSDVY] is down 2.69% over the past day.
Buy
76
PDEX alert for Apr 16
Pro-Dex [PDEX] is down 4.66% over the past day.
Buy
82
HAGHY alert for Apr 16
Hensoldt AG [HAGHY] is down 0.02% over the past day.
